Ginkgo Bioworks Holdings, Inc. $DNA Position Increased by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. increased its stake in Ginkgo Bioworks by 25.4% in Q1, now owning 686,767 shares valued at approximately $3.9 million.
• Wall Street analysts maintain a **consensus rating of "Hold"** on Ginkgo Bioworks, with a target price averaging $9.50, despite mixed ratings from various firms.
• Ginkgo Bioworks reported earnings of ($1.10) per share, beating expectations, with revenue of $49.6 million for the last quarter.

Goldman Sachs Group Inc. raised its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 25.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 686,767 shares of the company's stock after buying an additional 139,126 shares during the quarter. Goldman Sachs Group Inc. owned about 1.17% of Ginkgo Bioworks worth $3,915,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of DNA. US Bancorp DE lifted its holdings in Ginkgo Bioworks by 43.5% in the first quarter. US Bancorp DE now owns 6,302 shares of the company's stock valued at $36,000 after acquiring an additional 1,911 shares during the period. CWM LLC increased its holdings in shares of Ginkgo Bioworks by 667.6% in the 1st quarter. CWM LLC now owns 12,274 shares of the company's stock worth $70,000 after buying an additional 10,675 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Ginkgo Bioworks in the 1st quarter valued at approximately $76,000. Green Alpha Advisors LLC boosted its position in shares of Ginkgo Bioworks by 31.7% during the first quarter. Green Alpha Advisors LLC now owns 18,470 shares of the company's stock valued at $105,000 after buying an additional 4,449 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in Ginkgo Bioworks in the first quarter worth $120,000. 78.63% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on DNA. BTIG Research boosted their price target on Ginkgo Bioworks from $6.00 to $9.00 and gave the company a "sell" rating in a research note on Monday, August 25th. Cowen reissued a "buy" rating on shares of Ginkgo Bioworks in a report on Friday, August 8th. Finally, Wall Street Zen raised shares of Ginkgo Bioworks from a "sell" rating to a "hold" rating in a research note on Saturday, August 30th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $9.50.

Ginkgo Bioworks Price Performance

Shares of Ginkgo Bioworks stock traded up $0.35 during trading hours on Thursday, hitting $11.42. The company had a trading volume of 1,187,306 shares, compared to its average volume of 1,525,785. The company's 50-day moving average is $11.98 and its two-hundred day moving average is $9.32. The company has a market cap of $676.06 million, a P/E ratio of -1.95 and a beta of 1.50. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.00 and a twelve month high of $16.85.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.44) by $0.34. Ginkgo Bioworks had a negative net margin of 136.56% and a negative return on equity of 43.25%. The business had revenue of $49.60 million for the quarter, compared to the consensus estimate of $41.60 million. Ginkgo Bioworks has set its FY 2025 guidance at EPS. Sell-side analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.